WGS Earnings

WGS reported its earnings on 2026-02-23, showcasing a revenue of 120.99M against an estimate of 119.20M, resulting in a 1.5% surprise. The EPS was 0.14, surpassing the expected 0.11 by 27.27%. The stock experienced a 6.12% price change on the earnings day and a -0.83% change over the next five days, reflecting market reactions to the results.

Following WGS's earnings announcement on 2026-02-23, the stock price moved by 6.12% on the day of the release. Over the subsequent five days, it saw a -0.83% change. Historically, WGS's stock price tends to shift by an average of -5% in the 10 days leading up to earnings and 12.1% in the 10 days following, providing insight into potential market.

For 2026/Q1, analysts estimate WGS's annual revenue to reach 117.79M, while the EPS is projected at -0.01. These estimates reflect recent revisions, with revenue estimates revised upward by 0.03% and EPS estimates revised upward by 0.09% over the past three months, indicating analyst expectation in the company's performance.

The correlation between WGS's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were revised upward by 0.03%, while EPS estimates moved revised upward by 0.09%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, WGS's stock price typically moves by -5% in the 10 days before its earnings and 12.1% in the 10 days after. For the upcoming 2026/Q1 earnings, analysts expect an EPS of -0.01 and revenue of 117.79M.

The earnings call summary and Q&A indicate strong growth prospects with raised revenue guidance, robust exome and genome revenue growth, and increased adjusted gross margin. The company's strategic initiatives in NICU, pediatrics, and international markets, along with AI and automation investments, further enhance the outlook. Despite some uncertainties in the Q&A, the overall sentiment is positive, supported by optimism in new market penetration and operational efficiency improvements. The absence of negative catalysts like margin decline or guidance cuts solidifies the positive sentiment.